Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease.
Himanshu RaiSarika GuptaSaroj KumarJian YangSushil Kumar SinghChongzhao RanGyan ModiPublished in: Journal of medicinal chemistry (2022)
A person suspected of having Alzheimer's disease (AD) is clinically diagnosed for the presence of principal biomarkers, especially misfolded amyloid-beta (Aβ) and tau proteins in the brain regions. Existing radiotracer diagnostic tools, such as PET imaging, are expensive and have limited availability for primary patient screening and pre-clinical animal studies. To change the status quo, small-molecular near-infrared (NIR) probes have been rapidly developed, which may serve as an inexpensive, handy imaging tool to comprehend the dynamics of pathogenic progression in AD and assess therapeutic efficacy in vivo . This Perspective summarizes the biochemistry of Aβ and tau proteins and then focuses on structurally diverse NIR probes with coverages of their spectroscopic properties, binding affinity toward Aβ and tau species, and theranostic effectiveness. With the summarized information and perspective discussions, we hope that this paper may serve as a guiding tool for designing novel in vivo imaging fluoroprobes with theranostic capabilities in the future.
Keyphrases
- fluorescence imaging
- photodynamic therapy
- pet imaging
- living cells
- high resolution
- cerebrospinal fluid
- small molecule
- fluorescent probe
- randomized controlled trial
- single molecule
- case report
- cognitive decline
- healthcare
- blood brain barrier
- current status
- health information
- mass spectrometry
- pulmonary embolism
- positron emission tomography
- binding protein
- drug delivery
- quantum dots
- cerebral ischemia
- dna binding
- social media
- subarachnoid hemorrhage
- genetic diversity